Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Castrate Resistant Prostate Cancer

April 27, 2015

Join Benjamin I. Chung, MD and Sandy Srinivas, MD as they present their multidisciplinary expertise on a range of cases pertaining to castrate resistant prostate cancer.

Almost all advanced prostate cancers eventually become resistant to androgen deprivation therapy. Traditionally, docetaxel was the only life-prolonging treatment available for patients with metastatic castration-recurrent prostate cancer (CRPC), albeit with significant side effects. This has changed with a new wave of therapeutic options based on survival benefits including hormone therapy (abiraterone acetate and enzalutamide), immunotherapy (sipuleucel-T), alternate chemotherapy (cabazitaxel), and bone-modulating agents (denosumab and radium-223). The latest agent to receive approval is radium-223, an alpha-emitting radiopharmaceutical and the first bone-targeting agent to prolong overall survival in CRPC patients with bone metastases. Treatment decisions must be tailored individually depending on the presence or absence of symptoms, life expectancy, and performance status of the patient. Sequencing and combination of novel agents is an active area of research, as is the development of additional agents.

Target Audience

This educational activity is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Apply NCCN Guideline-based therapeutic strategies for the treatment of patients with castrate resistant prostate cancer
  • Identify key characteristics of patients who are candidates for active surveillance of prostate cancer
  • Describe the multidisciplinary aspects of the management of patients with castrate resistant prostate cancer
  • Identify the key characteristics of castrate resistant prostate cancer that trigger decision points
  • Recognize situations where optimal care may require adapting the Guideline recommendations to individual circumstances
Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca
  • Exelixis Inc.
  • Genentech BioOncology
  • Janssen Biotech, Inc.
  • Novartis Oncology
  • Takeda Oncology

Supported by a grant from Onyx Pharmaceuticals.

Supported by independent educational grants from Merck and Prometheus Laboratories Inc.

Supported by an unrestricted, educational grant from Celgene Corporation.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
04/27/2015
Course expires: 
07/02/2015
Event starts: 
04/27/2015 - 6:00pm
Event ends: 
04/27/2015 - 7:00pm
Cost:
$0.00

Benjamin I. Chung, MD
Stanford Cancer Institute

Sandy Srinivas, MD
Stanford Cancer Institute

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Accreditation Period

Course opens: 
04/27/2015
Course expires: 
07/02/2015

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing